Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of GEB-101 intrastromal corneal injection in TGFBI-related corneal dystrophy
CTR20263266Phase 2Active
- Sponsor
- 北京引正基因科技有限公司
- Start
- Sep 2026
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of GEB-101 in Corneal dystrophy, sponsored by 北京引正基因科技有限公司. Started Sep 2026; status: active.
02
Drugs
GEB-101
03
Conditions
Corneal dystrophy
Beyond the preview
Go deeper on CTR20263266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263266.